Our leadership includes noted experts from academia and industry who share a singular goal: to improve the lives of millions of patients who are suffering from primary axillary hyperhidrosis.
Andrew joined Dermira in April 2020 and serves as Chief Executive Officer and Chief Commercial Officer. He brings more than 30 years of global experience in the pharmaceutical and biotech industries to the organization.
Prior to joining Dermira, Andrew served as Chief Commercial Officer and Interim CEO of Immunocore, a privately held UK biotech company, where he built the commercial capabilities to prepare for the launch of the first pipeline asset.
He has served in a number of global leadership positions at Eli Lilly and Company across multiple therapeutic areas including immunology, dermatology, oncology, diabetes, neuroscience, and infectious diseases. While at Eli Lilly, he led multiple launches and built commercial capabilities in several countries. His positions included Senior Vice President Digital Ventures; President Europe, Australia and Canada; Vice President International Business Unit Oncology; General Manager, UK and Republic of Ireland; General Manager, Italy; and Group Brand Leader, US Affiliate.
Andrew has served on a number of industry trade association boards, including as Chairman of the European Markets Committee at EFPIA and as a board member of the BioIndustry Association in the UK.
Andrew has a degree in Biochemistry from the University of Cardiff.
Virginia joined Dermira in 2016 and currently serves as Chief Business Officer, SVP. Prior to the Lilly acquisition, Virginia served as VP of Corporate Development and Strategy for Dermira and led strategic partnering efforts and Dermira’s Alliance function.
Prior to joining Dermira, Virginia held various senior corporate and business development roles in biotech companies including DSM Biomedical, Intrexon Corporation, and FibroGen Inc., leading and executing numerous transactions across therapeutic areas including medical devices. In addition, Virginia has extensive corporate development and transaction experience both in the start-up environment (Cellastra Inc., EPL Technologies) and as a third-party consultant advising on business development initiatives.
Virginia holds an MBA from St. Joseph’s University and a BA from Temple University.
Bill joined Dermira in 2016 as SVP Medical Affairs and currently serves as Chief Scientific Affairs Officer. He brings 25 years of biotech R&D experience that includes a demonstrated a track record of success across biologics, small molecules, and therapeutic areas including oncology, neuropsychiatry, rheumatology, dermatology, and nephrology.
Prior to joining Dermira, Bill was Vice President for Medical Affairs at Neurocrine Biosciences and has held senior scientific and medical affairs roles with Merck Research Laboratories, where he served as Vice President, Global Center for Scientific Affairs, and Amgen, where he served as Vice President, Global Scientific Affairs. Bill also held positions of increasing responsibility with Novartis in the Global Business Development and Licensing group and with Bristol-Myers Squibb in the Medical Affairs group.
Bill earned his Pharm.D. from the University of Texas Health Science Center, San Antonio, and his B.S. in Pharmacy from the University of Texas, Austin.
Harp Dhaliwal joined Dermira in 2018 and currently serves as Senior Vice President, Supply Chain, Manufacturing and Procurement. Harp has 24 years of experience in engineering, operations strategy, manufacturing, and supply chain. Prior to Dermira, Harp was in a similar role with an oncology-focused company, Medivation, until its acquisition by Pfizer. Harp stayed on with Pfizer to lead the operations integration. Previously, Harp had a long career at Biogen, where he started as the Director of Clinical Supply Chain and progressed to roles with increasing levels of responsibility including the role of Chief Procurement Officer where he was responsible for managing $3 billion of enterprise-wide spend. Harp also has experience managing medical device operations with Boston Scientific. He spent the formative years of his career as an engineer with Fluor, as an entrepreneur with Paradigm Environmental, and as a management consultant with PRTM.
Harp holds a BASc in Chemical Engineering from the University of British Columbia and an MBA from Queen’s University in Canada.
Delphine currently serves as Senior Vice President, Pharmaceutical Sciences and oversees all technical development activities for the QBREXZA® (glycopyrronium) cloth franchise. Delphine joined Dermira in 2011 to establish Dermira’s fully virtual CMC, manufacturing, and supply chain capabilities enabling the successful development, approval, and launch of Qbrexza. Delphine has over 22 years of product development experience spanning all stages of development, small molecules and biologics. Prior to joining Dermira, Delphine served as Vice President, Pharmaceutical R&D at Anacor Pharmaceuticals, and held various leadership roles at ALZA Corporation (a Johnson & Johnson) and Cellegy Pharmaceuticals. Delphine conducted her postdoctoral training at the University of California, San Francisco, holds a Ph.D. in Pharmaceutical Sciences from the University of Cincinnati, and a Master’s degree in Chemical Engineering and Chemistry from Chimie ParisTech, Paris, France.
Gary joined Dermira in 2018 as Vice President, Compliance Officer to lead and manage all aspects of Dermira’s Compliance program, and he continues in that role. An attorney by background, Gary has over 25 years of experience as a Compliance professional, including serving in an enforcement role within the Office of Inspector General for the US Department of Health and Human Services (HHS); practicing law in the areas of compliance and health care fraud and abuse at Akin Gump Strauss Hauer & Feld, an international corporate law firm; working as a compliance consultant; and serving as a compliance officer for NuVasive, Inc., a small medical device company.
Gary earned his J.D. degree from Washington & Lee University School of Law, and a Bachelor of Arts from Claremont McKenna College. He has authored numerous articles and delivered speeches on corporate ethics and compliance issues as well as health care fraud and abuse.
Tracy VanDenBerg currently serves as Vice President, Head of Human Resources and has over 23 years of experience in Human Resources. Tracy joined Dermira in 2019 and previously led Total Rewards for the company in addition to her role as Senior Director, Human Resources Business Partner to the Product Development and Technical Operations organizations. Prior to Dermira, Tracy led Human Resources, Finance and Administration for Tencent America, LLC, and served in various Human Resources roles at TiVo, Boston Scientific, America Online, and Arthur Andersen, LLP. Tracy earned an MBA from San Jose State University and bachelor’s degrees in both Political Science and International Relations from the University of Southern California.
Our commercial leadership team has broad and extensive experience. Key facets of their expertise include market insights and analytics, launch planning and execution, market access preparation and management, consumer marketing, salesforce deployment, and life cycle management.
Andrew joined Dermira in April 2020 and serves as Chief Executive Officer and Chief Commercial Officer. He brings more than 30 years of global experience in the pharmaceutical and biotech industries to the organization.
Prior to joining Dermira, Andrew served as Chief Commercial Officer and Interim CEO of Immunocore, a privately held UK biotech company, where he built the commercial capabilities to prepare for the launch of the first pipeline asset.
He has served in a number of global leadership positions at Eli Lilly and Company across multiple therapeutic areas including immunology, dermatology, oncology, diabetes, neuroscience, and infectious diseases. While at Eli Lilly, he led multiple launches and built commercial capabilities in several countries. His positions included Senior Vice President Digital Ventures; President Europe, Australia and Canada; Vice President International Business Unit Oncology; General Manager, UK and Republic of Ireland; General Manager, Italy; and Group Brand Leader, US Affiliate.
Andrew has served on a number of industry trade association boards, including as Chairman of the European Markets Committee at EFPIA and as a board member of the BioIndustry Association in the UK.
Andrew has a degree in Biochemistry from the University of Cardiff.
Ray joined Dermira in June 2018 and serves as Vice President, Sales. In this role, he leads the sales organization, learning and development, and sales operations and analytics. He brings over 25 years of experience in the pharmaceutical and medical device industry.
Prior to joining Dermira, Ray served as Vice President, Sales at Allergan Medical. He also served in other sales leadership, sales, and marketing roles at Allergan, where he helped build teams, markets, and brands. Ray also has experience working for Roche Laboratories and Brasseler USA in various sales roles that increased his areas of responsibility in hospital and clinic settings. His industry experience includes medical dermatology, medical aesthetics, neuroscience, cardiology, and orthopedics.
Ray earned an MBA from Chapman University and a Bachelor of Science degree in Economics from the University of California, Riverside.
Ryan brings over 25 years of industry experience and currently serves as Vice President, Marketing and Market Access. He joined Dermira in 2017, leading the marketing and organizational launch readiness plans for the company. In 2018, Ryan’s scope was expanded to include leadership of both the Marketing and Market Access teams. In this role, Ryan and his teams lead the development and execution of commercialization plans across stakeholders to ensure success.
Prior to Dermira, Ryan served in various marketing leadership positions at Genentech. In these roles he led teams that successfully launched products in highly competitive markets. His experience also includes time spent at Roche in roles of increasing responsibility across Sales Leadership, Sales Operations, and Marketing. Ryan has depth and breadth of commercial expertise and a demonstrated ability to achieve success across biologic and small molecule markets in a variety of therapeutic areas.
Ryan earned his B.A. from St. Bonaventure University.
Carly Loeb joined Dermira in early 2018 and is Vice President, Commercial Insights and Operations. In this role, Carly leads the team responsible for commercial market research, data analytics, forecasting, and pricing and contracting analytics. Before Dermira, Carly led teams within the Market Analysis & Strategy function in Genentech’s Commercial organization, supporting pipeline and in-line franchises spanning endocrinology, oncology, neurology, and rare diseases. Prior to Genentech, Carly was a Project Leader at The Boston Consulting Group in the Healthcare Practice Area, supporting global health and biopharma clients with strategy development, post-merger integrations, and other transformations.
Carly holds a Ph.D in Biochemistry & Molecular Biology from the University of California, San Francisco and a B.S. in Biology with a minor in Economics from MIT.
Quality and Manufacturing work closely together to ensure that Dermira’s products are made to the highest quality standards. Irina Kasatkina, VP of Quality, leads Dermira’s Quality function.
Irina Kasatkina joined Dermira in 2019 and currently serves as Vice President of Quality. Irina brings over 20 years of multifaceted biopharmaceutical experience and a proven track record in quality and compliance functions. Prior to joining Dermira, Irina held senior quality and compliance roles at Genentech, where she led a wide range of quality functions and interfaced with regulatory agencies. Irina also has experience in manufacturing, supply chain, logistics management, and trade compliance.
Irina holds an M.S. Summa cum laude in Engineering and Technology of Food Industry from the National Academy of Food Technologies in Odessa, Ukraine.
